| Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial - BHE Jansen, YJL Bodar, GJC Zwezerijnen, D Meijer, JP Van Der Voorn, ... European journal of nuclear medicine and molecular imaging 48, 509-520, 2021 | 90 | 2021 |
| External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph … D Meijer, PJ van Leeuwen, MJ Roberts, AR Siriwardana, A Morton, ... European urology 80 (2), 234-242, 2021 | 50 | 2021 |
| Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer WI Luining, MCF Cysouw, D Meijer, NH Hendrikse, R Boellaard, AN Vis, ... Cancers 14 (5), 1169, 2022 | 36 | 2022 |
| Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible … YJL Bodar, BHE Jansen, JP Van Der Voorn, GJC Zwezerijnen, D Meijer, ... World journal of urology 39, 2439-2446, 2021 | 36 | 2021 |
| Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the … YJL Bodar, BGJC Zwezerijnen, PJ van der Voorn, BHE Jansen, RS Smit, ... European journal of nuclear medicine and molecular imaging, 1-12, 2022 | 24 | 2022 |
| The predictive value of preoperative negative prostate specific membrane antigen positron emission tomography imaging for lymph node metastatic prostate cancer D Meijer, HA de Barros, PJ van Leeuwen, YJL Bodar, HG van der Poel, ... The Journal of Urology 205 (6), 1655-1662, 2021 | 17 | 2021 |
| The prognostic value of lymph node staging with prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph … D Meijer, RH Ettema, PJ van Leeuwen, TH van der Kwast, ... BJU international 131 (3), 330-338, 2023 | 15 | 2023 |
| Prostate-specific membrane antigen positron emission tomography/computed tomography is associated with improved oncological outcome in men treated with salvage radiation … D Meijer, WSC Eppinga, RM Mohede, BGL Vanneste, P Meijnen, ... European urology oncology 5 (2), 146-152, 2022 | 15 | 2022 |
| Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: tumor localizations using PSMA PET/CT imaging D Meijer, ML Donswijk, YJL Bodar, PJ van Leeuwen, HG van der Poel, ... Journal of Nuclear Medicine 62 (7), 961-967, 2021 | 15 | 2021 |
| Reproducibility of PSMA PET/CT imaging for primary staging of treatment-naïve prostate cancer patients depends on the applied radiotracer: a retrospective study MJ Hagens, DE Oprea-Lager, AN Vis, M Wondergem, ML Donswijk, ... Journal of Nuclear Medicine 63 (10), 1531-1536, 2022 | 14 | 2022 |
| Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in … YJL Bodar, H Veerman, D Meijer, K de Bie, PJ van Leeuwen, ... BJU international 129 (6), 768-776, 2022 | 14 | 2022 |
| Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: A case … N van Ginkel, TJN Hermans, D Meijer, JL Boormans, J Voortman, ... International Urology and Nephrology 54 (12), 3145-3152, 2022 | 13 | 2022 |
| Nuclear imaging for bone metastases in prostate cancer: the emergence of modern techniques using novel radiotracers WI Luining, D Meijer, MR Dahele, AN Vis, DE Oprea-Lager Diagnostics 11 (1), 117, 2021 | 11 | 2021 |
| Predicting early outcomes in patients with intermediate‐and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic … D Meijer, PJ van Leeuwen, ML Donswijk, TN Boellaard, IG Schoots, ... BJU international 129 (1), 54-62, 2022 | 10 | 2022 |
| Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter … D Meijer, PJ van Leeuwen, PMJ Oosterholt, YJL Bodar, HG van der Poel, ... European journal of nuclear medicine and molecular imaging 48, 2960-2969, 2021 | 10 | 2021 |
| Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging … AN Vis, D Meijer, MJ Roberts, AR Siriwardana, A Morton, JW Yaxley, ... European Urology Oncology 6 (6), 553-563, 2023 | 9 | 2023 |
| Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer D Meijer, BHE Jansen, M Wondergem, YJL Bodar, S Srbljin, ... Plos one 15 (10), e0239414, 2020 | 9 | 2020 |
| Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk … LA van Riel, A Jager, D Meijer, AW Postema, RS Smit, AN Vis, ... Therapeutic advances in urology 14, 17562872221088536, 2022 | 8 | 2022 |
| Prostate cancer development is not affected by statin use in patients with elevated PSA levels D Meijer, RJA van Moorselaar, AN Vis, IV Bijnsdorp Cancers 11 (7), 953, 2019 | 8 | 2019 |
| Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer YJL Bodar, LMS Boevé, PJ van Leeuwen, PC Baars, JA Nieuwenhuijzen, ... BJU international 132 (6), 705-712, 2023 | 7 | 2023 |
Vis ANVumc在 vumc.nl 的电子邮件经过验证
